BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis

Reversion mutations are associated with clinical resistance to poly(ADP-ribose) polymerase inhibitors (PARPi). Here, we describe the detection of a BRCA1 reversion mutation in a 39-year-old woman with metastatic breast cancer harboring a heterozygous germline BRCA1 exons 7–8 deletion who received PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jia-Ni, Lei, Lei, Ye, Wei-Wu, Wang, Xiao-Jia, Cao, Wen-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Breast Cancer Society 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561137/
https://www.ncbi.nlm.nih.gov/pubmed/34652076
http://dx.doi.org/10.4048/jbc.2021.24.e39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561137/
https://www.ncbi.nlm.nih.gov/pubmed/34652076
http://dx.doi.org/10.4048/jbc.2021.24.e39

Ejemplares similares